Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Many cancer patients are prescribed drugs to which their cancer is already resistant - and
thus suffer toxicity with no potential for benefit. Previous attempts to assess
chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human
patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph
nodes in situ respond to standard of care therapeutics precisely microinjected with the
CIVO(tm) microdosing system.
Phase:
Phase 1
Details
Lead Sponsor:
Presage Biosciences
Collaborators:
Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH)